Our team supports a broad spectrum of biologics and peptide modalities, including:
Featured Service
Fast, Reliable Gene‑to‑Clinic Development
Bring your biologic program to life with an end‑to‑end CRADS platform
View service
What We Develop( CRADS)
CRADS – Our Development Expertise
- Monoclonal antibodies and antibody fragments
- Recombinant proteins
- PEGylated proteins
- Insulin analogs
- GLP-1 analogs
- Antibody-drug conjugates (ADC)
- Biosimilars, generic peptides and next-generation biologics
Our Facility Team
- Specialized research and development center designed to discover, design, develop, and scale biological therapeutics such as monoclonal antibodies, recombinant proteins, peptides, vaccines, gene therapies, and cell-based products.
- Strong team with biologics experience, exposure to multiple development stages, and a thorough understanding of regulatory expectations.
Key Highlights
- Fully integrated R&D and pilot-scale development suites.
- Platform technologies enabling rapid, phase-appropriate development.
- Strong quality systems and regulatory support.
Engineered for Success
- From gene construct to clinical-ready supply, we combine deep scientific expertise with agile execution to accelerate development timelines while maintaining the highest quality and regulatory standards.
Our Commitment
- We partner with you to advance your molecule with precision, speed, and confidence—delivering innovative biologics solutions aligned with your development goals.
Explore What We Develop( CRADS) services
Partner with India's foremost CRTO for GLP-compliant, globally accepted data.